Back

Prasugrel or clopidogrel in non-st-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention

28 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 6 - Pharmacogenetics - New sights on the horizon Antiplatelet Drugs ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Soojin Kim

Busan (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
Doctor A. Franci (Sao Paulo, BR)
Abstract Slides
Presentation thumbnail
Doctor K. Xu (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Doctor L. Gross (Munich, DE)
Abstract Slides
Presentation thumbnail
Mrs R. Olie (Maastricht, NL)
Abstract
Presentation thumbnail
Doctor J. Li (Busan, KR)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 6 - Pharmacogenetics - New sights on the horizon

The Event

Event poster

ESC Congress 2018

28 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Platelet inhibitory profiles of prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes undergoing percutaneous coronary intervention: results of a randomized feasibility study
1 September 2019
thumbnail
Congress Session
Implementation in real-world practice of ESC Guidelines for the acute management of patients with NSTE-ACS
27 August 2023
thumbnail
Congress Presentation
Impact of P2Y12 inhibitor pretreatment before coronary angiography in high risk NSTE-ACS: A comparative cohort analysis
21 March 2026
thumbnail
Congress Presentation
The optimization of dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction in dependence on the vasculoendothelial growth factor-A gene polymorphism G634C (rs2010963)
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources